NextCell Pharma AB Asset Resilience Ratio
NextCell Pharma AB asset resilience ratio. NextCell Pharma AB (NXTCL) has an Asset Resilience Ratio of -1.33% as of August 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of NextCell Pharma AB to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NextCell Pharma AB (2021–2024)
Asset resilience ratio of NextCell Pharma AB from 2021 to 2024. This chart shows how NextCell Pharma AB's Asset Resilience Ratio has changed over time. Read NextCell Pharma AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NextCell Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is NextCell Pharma AB's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-1.08 Million | -1.33% |
| Total Liquid Assets | Skr-1.08 Million | -1.33% |
Asset Resilience Insights
- Limited Liquidity: NextCell Pharma AB maintains only -1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NextCell Pharma AB Industry Peers by Asset Resilience Ratio
Compare NextCell Pharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
NextCell Pharma AB Asset Resilience Ratio by Year (2021–2024)
NextCell Pharma AB asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for NextCell Pharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-08-31 | -1.33% | Skr-1.08 Million ≈ $-116.43K |
Skr81.29 Million ≈ $8.75 Million |
-0.06pp |
| 2023-08-31 | -1.27% | Skr-1.13 Million ≈ $-121.75K |
Skr88.83 Million ≈ $9.56 Million |
-0.37pp |
| 2022-08-31 | -0.91% | Skr-1.13 Million ≈ $-121.41K |
Skr124.66 Million ≈ $13.41 Million |
-0.18pp |
| 2021-08-31 | -0.72% | Skr-1.13 Million ≈ $-121.41K |
Skr155.63 Million ≈ $16.75 Million |
-- |
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more